RxDoctor Payments Data

William Crane

Ophthalmology · Watertown, NYNPI 1558380964

Payments from drug & device makers

$2,243in general payments, 2019–2025

Across 86 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$377
  • Alcon$338
  • Mallinckrodt Hospital Products Inc.$242
  • Sun Pharmaceutical Industries Inc.$209
  • Tarsus Pharmaceuticals, Inc.$207
  • Bausch & Lomb Americas Inc.$199
  • plus $670 from 12 others

What the payments were for

  • Food & beverage$2,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,243 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$158,529
Medicare patients
358
Services billed
1,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast49$67,212
LumiganBimatoprost77$43,168
TyrvayaVarenicline Tartrate34$40,405
RestasisCyclosporine27$26,912
RocklatanNetarsudil Mesylat/Latanoprost44$23,339
Travoprost37$10,443
Brimonidine Tartrate65$8,037
Alphagan PBrimonidine Tartrate16$8,030
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$6,910
Prednisolone Acetate108$4,743
TafluprostTafluprost/Pf19$4,193
Loteprednol Etabonate14$2,647
Timolol Maleate97$2,433
Latanoprost231$2,391
Acetazolamide24$1,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$194$78,111120 claims
Bausch & Lomb Americas Inc.Xiidra$199$67,21249 claims
Oyster Point Pharma, Inc.Tyrvaya$377$40,40534 claims
Aerie Pharmaceuticals, Inc.Rocklatan$13$23,33944 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$2,64714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →